Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Prostatic Neoplasms 23Prostatic Neoplasms, Castration-Resistant 2Metastatic Castration-resistant Prostate Cancer 2Urogenital Neoplasms 1Thrombocytopenia 1Renal Insufficiency 1Prostatic Diseases 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Neoplasms by Site 1Neoplasms 1Metastatic Castration Resistant Prostate Cancer (mCRPC) 1Male Urogenital Diseases 1Liver Neoplasms 1Kidney Neoplasms 1High-Risk Localized Prostate Cancer 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Disease 1Cytopenia 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Astrocytoma 1Anemia 1

Interventions

decitabine and cedazuridine drug combination 1Pluvicto 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytopenia × Pluvicto × 90 days × Clear all
NCT07025512 2026-05-08

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Classical hematology

Cytopenia, Anemia, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡